Hematología y Hemoterapia

Resultados: 387
Tipo Título / Nombre Autor(es) Año
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group Boluda B, Sargas C, Ayala R..., Bergua J 2022
Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study Suárez E, Alonso JM, Boluda B..., Bergua J 2022
Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML) Simoes C, Villar S, Ariceta B..., Bergua J 2022
Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications Sargas C, Ayala R, Larryoz MJ..., Bergua J 2022
Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study) Labrador J, Martinez-Cuadron D, Boluda B..., Bergua J 2022
Concentración de hemoglobina reticulocitaria y ferroterapia en la ERC Deira J, García de la Vega C, Davín E, Arcos MJ 2022
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients Villar S, Ariceta B, Agirre X, Urribarri AD, Ayala R..., Bergua JM, et al 2022
Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study Ayala R, Carreño-Tarragona G, Barragán E, Boluda B, Larráyoz MJ..., Bergua J, et al 2022
Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) therapy in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL): results from the phase III Polarix study Flowers C, Tilly H, Morschhauser F, Sehn LH, Friedberg JW..., Bergua-Burgués JM, et al 2022
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries Bérard E, Röllig C, Bertoli S, Pigneux A, Tavitian S..., Bergua J, et al 2022